Changes in Cortical Volume with Olanzapine in Chronic Schizophrenia

Abstract

Introduction: Atypical antipsychotics can affect cortical volume differently from traditional drugs. The study of the outcome of grey matter deficits in schizophrenia with olanzapine may be of particular interest in this context.

Methods: In this study, we evaluated the changes in the volume of gray matter in the cortex of 11 schizophrenic patients treated with olanzapine and in 11 healthy controls after three years of follow-up. After MR imaging, acquisition data were processed with a volumetric quantification method based on the Talairach atlas. The longitudinal change of volumetric data was corrected for differences in overall brain size.

Results: Patients showed greater reduction than controls in cortical volume in the frontal and parietal regions during follow-up. No relationship was observed between clinical and volumetric changes.

Conclusion: Our data suggest that the profile of action of olanzapine on the cortical volume of chronically ill patients may be similar to that of typical antipsychotics. Other explanations, however, cannot be completely discarded for that outcome with our data.

References

• 1 Andreasen NC, Rajarethinam R, Cizadlo T, Arndt S, Swayze 2nd VW, Flashman LA, O’Leary DS, Ehrhardt JC, Yuh WT. Automatic atlas-based volume estimation of human brain regions from MR images.  J Comput Assist Tomogr. 1996;  20 98-106
• 2 Ashburner J, Friston KJ. Multimodal image coregistration and partitioning a unified framework.  Neuroimage. 1997;  6 209-217
• 3 Ashburner J, Friston KJ. Voxel-based morphometry the methods.  Neuroimage. 2000;  11 805-821
• 4 Bartzokis G, Beckson M, Lu PH, Nuechterlein KH, Edwards N, Mintz J. Age-related changes in frontal and temporal lobe volumes in men: a magnetic resonance imaging study.  Arch Gen Psychiatry. 2001;  58 461-465
• 5 Chard DT, Parker GJ, Griffin CM, Thompson AJ, Miller DH. The reproducibility and sensitivity of brain tissue volume measurements derived from an SPM-based segmentation methodology.  J Magn Reson Imaging. 2002;  15 259-567
• 6 Coffey CE, Wilkinson WE, Parashos IA, Soady SA, Sullivan RJ, Patterson LJ, Figiel GS, Webb MC, Spritzer CE, Djang WT. Quantitative cerebral anatomy of the aging human brain: a cross-sectional study using magnetic resonance imaging.  Neurology. 1992;  42 527-536
• 7 Dazzan P, Morgan KD, Orr K, Hutchinson G, Chitnis X, Suckling J, Fearon P, McGuire PK, Mallett RM, Jones PB, Leff J, Murray RM. Different effects of typical and atypical antipsychotics on grey matter in first episode psychosis: the AESOP study.  Neuropsychopharmacology. 2005;  30 765-774
• 8 Desco M, Pascau J, Reig S, Gispert JD, Santos A, Benito B, Molina V, Garcia-Barreno P. Multimodality image quantification using Talairach grid.  Proc SPIE Medical Imaging. 2001;  4422 1385-1392
• 9 Garver DL, Holcomb JA, Christensen JD. Cerebral cortical gray expansion associated with two second-generation antipsychotics.  Biol Psychiatry. 2005;  58 62-66
• 10 Gispert JD, Reig S, Pascau J, Vaquero JJ, Desco M. Repeatability of brain tissue volume quantification using magnetic resonance images. 10th Annual Meeting of the Organization for Human Brain Mapping, Budapest, Hungary.  Neuroimage. 2004;  22 ((suppl 1))
• 11 Gur RE, Cowell P, Turetsky BI, Gallacher F, Cannon T, Bilker W, Gur RC. A follow-up magnetic resonance imaging study of schizophrenia. Relationship of neuroanatomical changes to clinical and neurobehavioral measures.  Arch Gen Psychiatry. 1998;  55 145-152
• 12 Ho BC, Andreasen NC, Nopoulos P, Arndt S, Magnotta V, Flaum M. Progressive structural brain abnormalities and their relationship to clinical outcome: a longitudinal magnetic resonance imaging study early in schizophrenia.  Arch Gen Psychiatry. 2003;  60 585-594
• 13 Hollingshead A, Frederick R. Social stratification and psychiatric disorders.  Am Soc Rev. 1953;  18 163-189
• 14 Kates WR, Warsofsky IS, Patwardhan A, Abrams MT, Liu AM, Naidu S, Kaufmann WE, Reiss AL. Automated Talairach atlas-based parcellation and measurement of cerebral lobes in children.  Psychiatry Res. 1999;  91 11-30
• 15 Katsel P, Davis KL, Haroutunian V. Variations in myelin and oligodendrocyte-related gene expression across multiple brain regions in schizophrenia: A gene ontology study.  Schizophr Res. 2005;  79 157-173
• 16 Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia.  Schizophr Bull. 1987;  13 261-276
• 17 Keshavan MS, Haas GL, Kahn CE, Aguilar E, Dick EL, Schooler NR, Sweeney JA, Pettegrew JW. Superior temporal gyrus and the course of early schizophrenia: progressive, static, or reversible?.  J Psychiatr Res. 1998;  32 161-167
• 18 Lambert M, Conus P, Schimmelmann BG, Eide P, Ward J, Yuen H, Schacht M, Edwards J, Naber D, McGorry PD. Comparison of olanzapine and risperidone in 367 first-episode patients with non-affective or affective psychosis: results of an open retrospective medical record study.  Pharmacopsychiatry. 2005;  38 206-213
• 19 Lieberman JA, Tollefson GD, Charles C, Zipursky R, Sharma T, Kahn RS, Keefe RS, Green AI, Gur RE, McEvoy J, Perkins D, Hamer RM, Gu H, Tohen M. Antipsychotic drug effects on brain morphology in first-episode psychosis.  Arch Gen Psychiatry. 2005;  62 361-370
• 20 Mathalon DH, Sullivan EV, Lim KO, Pfefferbaum A. Progressive brain volume changes and the clinical course of schizophrenia in men: a longitudinal magnetic resonance imaging study.  Arch Gen Psychiatry. 2001;  58 148-157
• 21 McCormick L, Decker L, Nopoulos P, Ho BC, Andreasen N. Effects of atypical and typical neuroleptics on anterior cingulate volume in schizophrenia.  Schizophr Res. 2005;  80 73-84
• 22 Molina V, Gispert JD, Reig S, Pascau J, Palomo T, Martínez R, Desco M. Olanzapine-induced cerebral metabolic changes. Relation to symptom changes in schizophrenia.  Int Clin Psychopharmacol. 2005;  20 13-18
• 23 Molina V, Gispert JD, Reig S, Sanz J, Pascau J, Santos A, Desco M, Palomo T. Cerebral metabolic changes induced by clozapine in schizophrenia.  Psychopharmacology. 2005;  178 17-26
• 24 Molina V, Gispert JD, Reig S, Sanz J, Pascau J, Santos A, Palomo T, Desco M. Cerebral metabolism and risperidone treatment in schizophrenia.  Schizophrenia Res. 2003;  60 1-7
• 25 Molina V, Reig S, Sanz J, Palomo T, Benito C, Sánchez J, Sarramea F, Pascau J, Desco M. Increase in gray matter volume and decrease in white matter volume in the cerebral cortex during treatment with atypical neuroleptics in schizophrenia.  Schizophrenia Res. 2005;  80 61-71
• 26 Molina V, Reig S, Sarramea F, Sanz J, FArtaloytia J, Luque R, Aragüés M, Pascau J, Benito C, Palomo T, Desco M. Anatomical and functional brain variables associated to clozapine response in treatment-resistant schizophrenia.  Psychiatry Res:Neuroimaging. 2003;  124 153-161
• 27 Pantelis C, Velakoulis D, McGorry PD, Wood SJ, Suckling J, Phillips LJ, Yung AR, Bullmore ET, Brewer W, Soulsby B, Desmond P, McGuire PK. Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison.  Lancet. 2003;  361 281-288
• 28 Pfefferbaum A, Lim KO, Zipursky RB, Mathalon DH, Rosenbloom MJ, Lane B, Ha CN, Sullivan EV. Brain gray and white matter volume loss accelerates with aging in chronic alcoholics: a quantitative MRI study.  Alcohol Clin Exp Res. 1992;  16 1078-1089
• 29 Rajkowska G, Miguel-Hidalgo JJ, Makkos Z, Meltzer H, Overholser J, Stockmeier C. Layer-specific reductions in GFAP-reactive astroglia in the dorsolateral prefrontal cortex in schizophrenia.  Schizophr Res. 2002;  57 127-138
• 30 Selemon LD, Lidow MS. Goldman-Rakic PS Increased volume and glial density in primate prefrontal cortex associated with chronic antipsychotic drug exposure.  Biol Psychiatry. 1999;  46 161-172
• 31 Selemon LD, Rajkowska G. Goldman-Rakic PS Abnormally high neuronal density in the schizophrenic cortex. A morphometric analysis of prefrontal area 9 and occipital area 17.  Arch Gen Psychiatry. 1995;  52 805-818
• 32 Selemon LD, Rajkowska G. Goldman-Rakic PS Elevated neuronal density in prefrontal area 46 in brains from schizophrenic patients: application of a three-dimensional, stereologic counting method.  J Comp Neurol. 1998;  392 402-412
• 33 Sowell ER, Peterson BS, Thompson PM, Welcome SE, Henkenius AL, Toga AW. Mapping cortical change across the human life span.  Nat Neurosci. 2003;  6 309-315
• 34 Stark AK, Uylings HB, Sanz-Arigita E, Pakkenberg B. Glial cell loss in the anterior cingulate cortex, a subregion of the prefrontal cortex, in subjects with schizophrenia.  Am J Psychiatry. 2004;  161 882-888
• 35 Szulc A, Galinska B, Tarasow E, Dzienis W, Kubas B, Konarzewska B, Walecki J, Alathiaki AS, Czernikiewicz A. The effect of risperidone on metabolite measures in the frontal lobe, temporal lobe, and thalamus in schizophrenic patients. A proton magnetic resonance spectroscopy (1 H MRS).  Pharmacopsychiatry. 2005;  38 214-219
• 36 Talairach J, Tournoux P. Co-planar Stereotaxic Atlas of the Human Brain. Thieme Medical, Stuttgart, New York 1988
• 37 Uranova NA, Vostrikov VM, Orlovskaya DD, Rachmanova VI. Oligodendroglial density in the prefrontal cortex in schizophrenia and mood disorders: a study from the Stanley Neuropathology Consortium.  Schizophr Res. 2004;  67 269-275

Correspondence